Stock Events

Stock Events

Mosaic ImmunoEngineering 

$0.082500
2
-$0.05-39.78%Friday 19:57

Statistics

Day High
0.06
Day Low
0.06
52W High
0.89
52W Low
0.054
Volume
2
Avg. Volume
620
Mkt Cap
597,465
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Apr 2007
$10.00
Mar 2006
$10.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Jan 10Expected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-0.15
-0.1
-0.05
0
Expected EPS
0
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-688,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology, which is a platform that can be used for developing vaccines, potentially competing with Mosaic's virus-like particle (VLP) technology.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech, similar to Moderna, focuses on mRNA technology for vaccines and therapeutics, directly competing in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.66B
Novavax specializes in vaccine development using nanoparticle technology, which could be seen as a direct competitor to Mosaic's VLP-based vaccine approach.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, with its broad range of vaccines and partnership with BioNTech on COVID-19 vaccine, competes in the vaccine and immunotherapy market.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines, including its adenovirus-based COVID-19 vaccine, competing in the same space as Mosaic.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a significant presence in the vaccine market, including development of adjuvant systems that could compete with Mosaic's technology.
Sanofi
SNY
Mkt Cap106.24B
Sanofi focuses on vaccines and immune therapies, including collaborations on mRNA vaccines, making it a competitor in the immunotherapy field.
Merck
MRK
Mkt Cap368.89B
Merck is involved in vaccine development and immunotherapy, including efforts in viral vector vaccines, which could be seen as competing technologies to Mosaic's.
Arbutus Biopharma
ABUS
Mkt Cap881.57M
Arbutus Biopharma works on lipid nanoparticle delivery systems for RNA therapies, which could be used in competing vaccine technologies.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics focuses on gene editing, a technology that could potentially be used to develop novel immunotherapies, competing with Mosaic's approach.

About

Mosaic ImmunoEngineering Inc. is an early-stage biotechnology firm dedicated to the advancement and commercialization of an immunomodulatory platform technology. This innovative platform aims to provide therapeutic solutions for cancer and infectious diseases in both human and animal health. The company's core product is MIE-101, a nanoparticle-based treatment sourced from the cowpea mosaic virus, which has demonstrated non-infectious characteristics in mice, dogs, and humans. Headquartered in Novato, California, the company commenced operations in 2020.
Show More
CEO
Steven W. King
Employees
7
Country
United States
ISIN
US61945M1018

Listings

OTC Link
US
CPMV

0 Comments

Share your thoughts

FAQs

What is Mosaic ImmunoEngineering stock price today?▼
The current price of CPMV is $0.08 USD — it has decreased by -39.78% in the past 24 hours. Watch Mosaic ImmunoEngineering stock price performance more closely on the chart.
What is Mosaic ImmunoEngineering stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Mosaic ImmunoEngineering stocks are traded under the ticker CPMV.
Is Mosaic ImmunoEngineering stock price growing?▼
CPMV stock has fallen by -54.17% compared to the previous week, the month change is a -22.17% fall, over the last year Mosaic ImmunoEngineering has showed a -90.16% decrease.
What is Mosaic ImmunoEngineering market cap?▼
Today Mosaic ImmunoEngineering has the market capitalization of 597,465
What is Mosaic ImmunoEngineering revenue for the last year?▼
Mosaic ImmunoEngineering revenue for the last year amounts to 0 USD.
What is Mosaic ImmunoEngineering net income for the last year?▼
CPMV net income for the last year is -688,000 USD.
Does Mosaic ImmunoEngineering pay dividends?▼
Yes, CPMV dividends are paid annual. The last dividend per share was 10 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Mosaic ImmunoEngineering have?▼
As of November 2, 2026, the company has 7 employees.
In which sector is Mosaic ImmunoEngineering located?▼
Mosaic ImmunoEngineering operates in the Health & Wellness sector.
When did Mosaic ImmunoEngineering complete a stock split?▼
The last stock split for Mosaic ImmunoEngineering was on December 2, 2020 with a ratio of 1:500.
Where is Mosaic ImmunoEngineering headquartered?▼
Mosaic ImmunoEngineering is headquartered in Huntington Beach, United States.